Stonepine Capital Management LLC Acquires Shares of 137,174 Aprea Therapeutics, Inc. (NASDAQ:APRE)

Stonepine Capital Management LLC acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up approximately 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest holding. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent reporting period.

Separately, Dimensional Fund Advisors LP purchased a new stake in shares of Aprea Therapeutics in the second quarter valued at about $45,000. 34.19% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $2.75 on Tuesday. Aprea Therapeutics, Inc. has a 1-year low of $2.25 and a 1-year high of $8.85. The firm has a market cap of $14.93 million, a PE ratio of -0.83 and a beta of 1.04. The company has a 50-day moving average of $3.40 and a two-hundred day moving average of $4.48.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. The firm had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. Sell-side analysts anticipate that Aprea Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on APRE shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, August 12th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, August 13th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.